|
1
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jerjes W, Upile T, Petrie A, Riskalla A,
Hamdoon Z, Vourvachis M, Karavidas K, Jay A, Sandison A, Thomas GJ,
et al: Clinicopathological parameters, recurrence, locoregional and
distant metastasis in 115 T1-T2 oral squamous cell carcinoma
patients. Head Neck Oncol. 2:92010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. New Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
5
|
O'Dwyer PJ, Stevenson JP and Johnson SW:
Clinical pharmacokinetics and administration of established
platinum drugs. Drugs. 59(Suppl 4): 19–27. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baruah H, Barry CG and Bierbach U:
Platinum-intercalator conjugates: From DNA-targeted cisplatin
derivatives to adenine binding complexes as potential modulators of
gene regulation. Curr Top Med Chem. 4:1537–1549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimanishi M, Ogi K, Sogabe Y, Kaneko T,
Dehari H, Miyazaki A and Hiratsuka H: Silencing of GLUT-1 inhibits
sensitization of oral cancer cells to cisplatin during hypoxia. J
Oral Pathol Med. 42:382–388. 2013. View Article : Google Scholar
|
|
8
|
Perez RP: Cellular and molecular
determinants of cisplatin resistance. Eur J Cancer. 34:1535–1542.
1998. View Article : Google Scholar
|
|
9
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar :
|
|
10
|
Cohen SM and Lippard SJ: Cisplatin: From
DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol.
67:93–130. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnson DH: Evolution of cisplatin-based
chemotherapy in non-small cell lung cancer: A historical
perspective and the eastern cooperative oncology group experience.
Chest. 117(Suppl 1): S133–S137. 2000. View Article : Google Scholar
|
|
12
|
Maitra A, Wistuba II, Washington C,
Virmani AK, Ashfaq R, Milchgrub S, Gazdar AF and Minna JD:
High-resolution chromosome 3p allelotyping of breast carcinomas and
precursor lesions demonstrates frequent loss of heterozygosity and
a discontinuous pattern of allele loss. Am J Pathol. 159:119–130.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zabarovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lerman MI and Minna JD: The 630-kb lung
cancer homozygous deletion region on human chromosome 3p21.3:
Identification and evaluation of the resident candidate tumor
suppressor genes. The international lung cancer chromosome 3p213
tumor suppressor gene consortium. Cancer Res. 60:6116–6133.
2000.PubMed/NCBI
|
|
15
|
Angell JE, Lindner DJ, Shapiro PS, Hofmann
ER and Kalvakolanu DV: Identification of GRIM-19, a novel cell
death-regulatory gene induced by the interferon-beta and retinoic
acid combination, using a genetic approach. J Biol Chem.
275:33416–33426. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li M, Li Z, Liang C, Han C, Huang W and
Sun F: Upregulation of GRIM-19 suppresses the growth of oral
squamous cell carcinoma in vitro and in vivo. Oncolo Rep.
32:2183–2190. 2014.
|
|
17
|
Ou W, Ye S, Yang W, Wang Y, Ma Q, Yu C,
Shi H, Yuan Z, Zhong G, Ren J, et al: Enhanced antitumor effect of
cisplatin in human NSCLC cells by tumor suppressor LKB1. Cancer
Gene Ther. 19:489–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nemunaitis J, Swisher SG, Timmons T,
Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp
BL, et al: Adenovirus-mediated p53 gene transfer in sequence with
cisplatin to tumors of patients with non-small-cell lung cancer. J
Clin Oncol. 18:609–622. 2000.PubMed/NCBI
|
|
19
|
Ueda K, Kawashima H, Ohtani S, Deng WG,
Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA, et al:
The 3p21.3 tumor suppressor NPRL2 plays an important role in
cisplatin-induced resistance in human non-small-cell lung cancer
cells. Cancer Res. 66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deng WG, Wu G, Ueda K, Xu K, Roth JA and
Ji L: Enhancement of antitumor activity of cisplatin in human lung
cancer cells by tumor suppressor FUS1. Cancer Gene Ther. 15:29–39.
2008. View Article : Google Scholar
|
|
21
|
Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao
W, Fu A, Cai L, Li X, Ye X, et al: Improved tumor-targeting drug
delivery and therapeutic efficacy by cationic liposome modified
with truncated bFGF peptide. J Control Release. 145:17–25. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in vivo. Oncol Rep.
31:1954–1960. 2014.PubMed/NCBI
|
|
23
|
Lowe SW, Ruley HE, Jacks T and Housman DE:
p53-dependent apoptosis modulates the cytotoxicity of anticancer
agents. Cell. 74:957–967. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu JR, Opipari AW, Tan L, Jiang Y, Zhang
Y, Tang H and Nuñez G: Dysfunctional apoptosome activation in
ovarian cancer: Implications for chemoresistance. Cancer Res.
62:924–931. 2002.PubMed/NCBI
|
|
25
|
Wurstle ML, Zink E, Prehn JH and Rehm M:
From computational modelling of the intrinsic apoptosis pathway to
a systems-based analysis of chemotherapy resistance: Achievements,
perspectives and challenges in systems medicine. Cell Death Dis.
5:e12582014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niedner H, Christen R, Lin X, Kondo A and
Howell SB: Identification of genes that mediate sensitivity to
cisplatin. Mol Pharmacol. 60:1153–1160. 2001.PubMed/NCBI
|
|
27
|
Park SA, Park HJ, Lee BI, Ahn YH, Kim SU
and Choi KS: Bcl-2 blocks cisplatin-induced apoptosis by
suppression of ERK-mediated p53 accumulation in B104 cells. Brain
Res Mol Brain Res. 93:18–26. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Gao L, Li Y, Lin G, Shao Y, Ji K,
Yu H, Hu J, Kalvakolanu DV, Kopecko DJ, et al: Effects of
plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3
M tumor cell growth. Clin Cancer Res. 14:559–568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kumar B, Yadav A, Hideg K, Kuppusamy P,
Teknos TN and Kumar P: A novel curcumin analog (H-4073) enhances
the therapeutic efficacy of cisplatin treatment in head and neck
cancer. PloS One. 9:e932082014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han Z, Feng J, Hong Z, Chen L, Li W, Liao
S, Wang X, Ji T, Wang S, Ma D, et al: Silencing of the STAT3
signaling pathway reverses the inherent and induced chemoresistance
of human ovarian cancer cells. Biochem Biophys Res Commun.
435:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou Y, Li M, Wei Y, Feng D, Peng C, Weng
H, Ma Y, Bao L, Nallar S, Kalakonda S, et al: Downregulation of
GRIM-19 expression is associated with hyperactivation of
STAT3-induced gene expression and tumor growth in human cervical
cancers. J Interferon Cytokine Res. 29:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hao H, Liu J, Liu G, Guan D, Yang Y, Zhang
X, Cao X and Liu Q: Depletion of GRIM-19 accelerates hepatocellular
carcinoma invasion via inducing EMT and loss of contact inhibition.
J Cell Physiol. 227:1212–1219. 2012. View Article : Google Scholar
|
|
36
|
Okamoto T, Inozume T, Mitsui H, Kanzaki M,
Harada K, Shibagaki N and Shimada S: Upregulation of GRIM-19 in
cancer cells suppresses STAT3-mediated signal transduction and
cancer growth. Mol Cancer Ther. 9:2333–2343. 2010. View Article : Google Scholar : PubMed/NCBI
|
